NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE1, PHASE2

Sponsor: Essen Biotech

Condition: Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer, Melanoma (Skin Cancer), Bladder Cancer, Kidney Cancer, Pancreatic Cancer Metastatic, Liver Cancer (Primary and Metastatic), Ovarian Cancer, Esophageal Cancer, Glioblastoma, Non-Melanoma Skin Cancer

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal | complex_intervention_signal

Stopped reason

Context when available

No stop reason available in the current public record.